

ISSUES IN HEPATITIS B VIRUS INFECTION:

CURRENT THERAPIES, PREVENTING RESISTANCE, SPECIAL PATIENT POPULATIONS

Supplement 3 to Volume 76 • May 2009

Supplement Editor

WILLIAM D. CAREY, MD
Cleveland Clinic

This supplement is based on a symposium, "B-SMART: Hepatitis B," convened at Cleveland Clinic on December 6, 2008. The symposium was part of the "Seventh Annual Liver Update," a CME activity sponsored by the Cleveland Clinic Center for Continuing Education.

Contents

The prevalence and natural history of hepatitis B in the 21st century.....	S2	Monotherapy vs multiple-drug therapy: The experts debate.....	S20
William D. Carey, MD		Robert G. Gish, MD, and Pierre M. Gholam, MD	
Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment	S6	Management of hepatitis B in pregnancy: Weighing the options	S25
Morris Sherman, MD, PhD		Tram T. Tran, MD	
Understanding cultural barriers in hepatitis B virus infection.....	S10	Strategies for managing coinfection with hepatitis B virus and HIV.....	S30
Tram T. Tran, MD		Morris Sherman, MD, PhD	
Hepatitis B treatment: Current best practices, avoiding resistance	S14		
Robert G. Gish, MD			

Acknowledgment

This supplement was supported by educational grants from Bristol-Myers Squibb Company, whose products include entecavir, and Gilead Sciences, Inc., whose products include adefovir, emtricitabine, and tenofovir. These products are among the therapies discussed in this supplement.

Topics and editors for supplements to the *Cleveland Clinic Journal of Medicine* are determined by the *Journal's* editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The *Journal* ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter. For full guidelines on grant-supported supplements to the *Journal*, go to www.ccjm.org/site/misc/Supplement_Guidelines.pdf.

Author and Editor Disclosures

William D. Carey, MD, reported that he has no financial relationships that could be perceived as a potential conflict of interest in the context of his contributions to this supplement.

Pierre M. Gholam, MD, reported that he has received grant/research support from Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals, Inc., Gilead Sciences, Inc., Roche Pharmaceuticals, and Sanofi-Aventis; and consulting fees and honoraria for teaching and speaking from Gilead Sciences, Inc., Onyx Pharmaceuticals, and Vertex Pharmaceuticals.

Robert G. Gish, MD, reported that he has received consulting fees, honoraria for speaker programs, and research grants

from Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Idenix/Novartis, Innogenetics, Merck, Metabasis Therapeutics, Pharmasset, Roche Laboratories, Inc., Schering-Plough, and SciClone Pharmaceuticals.

Morris Sherman, MD, PhD, reported that he has received consulting fees and honoraria for teaching and speaking from Bristol-Myers Squibb Company, Gilead Sciences, Inc., and Roche Laboratories, Inc.

Tram T. Tran, MD, reported that she has no financial relationships that could be perceived as a potential conflict of interest in the context of her contributions to this supplement.